Alectos (Canada)

Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice

Nicholas B. Hastings, Xiaohai Wang, Lixin Song et al. · Molecular Neurodegeneration · 2017 · 148 citations · Full text

Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies

Harold G. Selnick, J. Fred Hess, Cuyue Tang et al. · Journal of Medicinal Chemistry · 2019 · 134 citations · Full text

Structures of lactate dehydrogenase A (LDHA) in apo, ternary and inhibitor-bound forms

S. Kolappan, David L. Shen, Renée Mosi et al. · Acta Crystallographica Section D Biological Crystallography · 2015 · 76 citations

Molecular Biology, Molecular Pharmacology, Structure-function Enzyme Kinetics +17

P4‐036: Pharmacokinetics and Pharmacodynamics to Support Clinical Studies of MK‐8719: an O‐Glcnacase Inhibitor for Progressive Supranuclear Palsy

Punam Sandhu, Junghoon Lee, Jeanine Ballard et al. · Alzheimer s & Dementia · 2016 · 25 citations

Pharmacological Study, Biochemistry, Mk-8719 Administration +12

O2‐13‐04: Early Clinical Results and Preclinical Validation of the O‐Glcnacase (OGA) Inhibitor Mk‐8719 as a Novel Therapeutic for the Treatment of Tauopathies

Sean M. Smith, Arie Struyk, Daniel Jonathan et al. · Alzheimer s & Dementia · 2016 · 23 citations

Translational Medicine, Neurodegenerative Diseases, Target Engagement +15